Deutsche Bank Research has lowered its price target for Fresenius Medical Care from 40 to 38 euros, while maintaining a 'Hold' rating. This adjustment follows the company's Q3 financial reporting and reflects ongoing structural headwinds despite internal operational improvements.
Deutsche Bank Research has reduced its price target for Fresenius Medical Care (FME) from 40 to 38 euros, while keeping a 'Hold' rating. This decision stems from the company's third-quarter financial reporting and analyst Falko Friedrichs' observation of persistent 'significant structural headwinds,' even as management focuses on internal operational improvements. The lowered price target suggests a slightly more cautious outlook on the company's near-term valuation, impacting investors holding or considering FME shares. While not a 'Sell' rating, the 'Hold' combined with a reduced target indicates that the bank sees limited upside potential in the short term, despite acknowledging internal efforts. This could lead to minor downward pressure on FME's stock price as the market digests the revised valuation.